Compare Microsoft (MSFT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Summit Therapeutics Inc — how do they compare? Microsoft trades at $535.07 (market cap $3.88T), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Microsoft is far larger — about 283× Summit Therapeutics Inc's market cap, and Microsoft pays a 0.75% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Summit Therapeutics Inc for 16 Days on average.
| MSFT | SMMT | |
|---|---|---|
Market Cap | $3.88T | $13.71B |
Volume | 19,593,392 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $542.07 | $26.38 |
52-Week Low | $352.83 | $12.43 |
Typical Hold Time | 142 Days | 16 Days |
Enterprise Value | $3.86T | $13.04B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $522.61, down 1.35% on the day, with strong technical support at $517 and resistance at $530. The company demonstrates robust fundamentals with 2025 revenue of $281.72B and net income of $101.83B, maintaining a 40.31% net margin. Recent earnings beats and bullish analyst consensus support the stock's long-term growth trajectory despite near-term volatility.
Outlook remains positive with 81.7% analyst buy ratings and $571.76 consensus price target, representing 9.4% upside. Key risks include increased capital expenditure concerns and competitive pressures in AI, but Microsoft's strong cloud positioning and consistent earnings growth provide solid foundation for investor confidence.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported no revenue in 2025 and a net loss of $1.08 billion, but recent news of a $2 billion strategic investment from AstraZeneca and clinical collaborations has driven significant positive sentiment. Analyst consensus is strongly bullish with a $29.33 price target, reflecting optimism around its cancer drug pipeline.
The outlook hinges on successful clinical trials for ivonescimab, with potential upside from partnership milestones. Key risks include high cash burn, reliance on pipeline success, and competitive pressures. Investors should weigh the speculative nature of biotech investing against the substantial institutional backing and analyst confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
